

# Index

## A

ACS. *See* Acute coronary syndrome (ACS)

Activated partial thromboplastin time (aPTT), 241, 242

Acute cholangitis

broad-spectrum penicillins, 138

endoscopic drainage, 138, 139

laboratory findings, 138

malignancy-related causes, 138

percutaneous drainage, 139

symptoms, 138

Acute coronary syndrome (ACS)

cancer treatment

bevacizumab, 72

5-fluorouracil (FU), 72

ischemia, 73

Krebs cycle, 72

tyrosine kinase inhibitors, 72

vascular endothelial growth factor, 73

conservative vs. early invasive

strategy, 73

definition, 65

diagnosis, 66

early risk stratification, 66

management, 68

anti-inflammatory treatment, 72

anti-ischemic therapy, 67

antiplatelet therapy (*see* Antiplatelet/  
antithrombotic therapy)

pathogenesis, 65

Acute deep VTE

cancer patients, 249

clinical manifestations, 223

diagnosis, 224, 225

patients with cancer, 222

risk of, 223

treatment, 226–228

Acute hemorrhage, 250

assessment, 241–243

cancer and treatments, 240

causes of, 240

management, 243–245

Acute kidney injury (AKI)

acute tubular necrosis, 146

dialysis, 147

intravenous (IV) hydration, 146

intrinsic renal disease, 144, 145

optimal fluid-based therapy, 146

PCN, 146–147

postrenal obstruction, 144, 145

prerenal azotemia, 144–146

renal function, 146

renal replacement therapy, 144

RIFLE criteria, 144–146

TLS, 147

urinary obstruction, 146

Acute pain, 277–278

Acute pancreatitis

clinical presentation, 135, 136

complications, 137

diagnosis, 136

etiology, 135

magnetic resonance

cholangiopancreatography, 137

radiologic investigations, 136–137

treatment, 138

Acute retinal necrosis, 380

Adjuvant analgesics, 279, 284

Adrenal crisis

cortisol level, 44

- Adrenal crisis (*cont.*)  
 glucocorticoid synthesis, 43  
 hypothalamic-pituitary area, 43, 44  
 intravenous push, 45  
 metastasis, 43
- Adrenal insufficiency, 44
- $\alpha$ -Adrenergic medications, 320
- Adverse effects  
 antiemetics, 300  
 corticosteroids, 301  
 immunomodulators, 301  
 immunosuppressants, 301  
 psychotropics, 301  
 serotonin syndrome, 301
- Agitation  
 delirium, 290–300, (*see also* Delirium)  
 description, 288  
 management, 288, 289  
 medical cause, 289  
 oncology setting, 290
- Akathisia, 300
- AKI. *See* Acute kidney injury (AKI)
- Alemtuzumab, 262
- Alkylating agents, 257
- Allredge, B.K., 8
- Allergic reaction  
 alveolitis, 257  
 medications, 255
- Anderson, J.L., 77
- Anderson, P.M., 313–325
- Anemia, 250  
 cancer patients, 231  
 evaluation, 232  
 hemolytic, 235, 236  
 management, 234  
 peripheral blood smear, 233  
 RBC production, 236, 237  
 spectrum of, 231
- Anthracyclines  
 DNA and RNA synthesis, 266  
 treatment, 266
- Anticholinergics, 296
- Anticoagulation, 226, 227
- Antidiuretic hormone secretion, 23
- Antiemetics, 300, 301
- Antiplatelet/antithrombotic therapy  
 adenosine diphosphate receptor  
 antagonists  
 CABG, 69  
 clopidogrel, 68  
 PCI, 69  
 ticagrelor, 69  
 ticlopidine, 68  
 UA and NSTEMI, 68
- anticoagulation  
 enoxaparin, 70  
 fondaparinux, 70  
 UFH, 69  
 aspirin, 68  
 GP IIb/IIIa inhibitors, 70–71  
 heparin-induced thrombocytopenia  
 patients, 71
- Antipsychotics  
 atypical, 298, 300  
 benzodiazepines, 303  
 haloperidol, 298  
 management, 293  
 pharmacologic treatment, 298  
 psychosis, 306
- Anxiety, 304–305
- Aplastic anemia, 236
- Aripiprazole, 300
- Arthritis  
 definition, 162  
 monoarthritis  
 associated with malignancy, 165  
 crystal-induced arthritis, 164–165  
 diagnosis and treatment, 165–167  
 septic, 163–164  
 oligoarthritis, 167, 168  
 polyarthritis, 167, 168
- Ascites  
 cancer cells, 131  
 chylous, 131  
 cirrhosis/portal hypertension, 131  
 clinical manifestations, 131  
 evaluation, 131, 132  
 factors, 131  
 treatment, 132
- Asparaginase, 257
- Aspiration pneumonia  
 acute/chronic phase, 100  
 barium swallow, 101  
 factors, 100  
 fiber-optic endoscopic evaluation, 101  
 metastatic brain lesions, 100  
 oropharyngeal flora, 101  
 primary brain tumors, 100  
 swallowing dysfunction, 100  
 treatment, 101
- Atrioventricular (AV) blocking agents, 57
- Autoimmune hemolytic anemia, 236
- B**
- Babber, P., 93–96, 98–103, 105–110
- Babinski sign, 5
- Bacterial vaginosis (BV), 340

- Bartholin glands, 338  
 Beevor sign, 5  
 Benzodiazepines, 296, 298, 301, 302, 305  
 BK virus, 145, 154  
 Blood transfusion reactions  
   acute hemolytic transfusion reactions, 245–247  
   bacterial contamination, 247, 248  
   clinical presentation, 245  
   common dilemma, 245  
   early management, 245  
   severe allergic (anaphylactic) reactions, 248, 249  
     TRALI, 245, 247  
 Bodurka, D.C., 327–347  
 Bradycardia, 60  
 Brock, P., 1–18
- C**  
 CABG. *See* Coronary artery bypass grafting (CABG)  
 Cachexia  
   assessment, 281  
   management, 281  
   pathogenesis, 280  
 Campagna, M.-C., 93–9698–103, 105–110, 113–139  
 Cancer  
   acute pain, 277  
   anorexia, 280  
   cachexia, 280  
   chronic pain, 276  
   complications, 281  
   emergency care, 274  
   ethical considerations, 282  
   etiology, 275  
   non-cancer-related pain, 275  
   psychosocial distress, 276  
   risk prediction model score, 205  
   and treatment, skeletal complications  
     avascular necrosis, 174–175  
     osteoporotic fractures, 173–174  
     primary and metastatic musculoskeletal tumors, 172, 173  
     side effects, 372, 388  
   uncontrolled, 275  
 Cancer patient  
   analgesics, 185  
   etiology, 185  
   hip pain  
     EC, 184  
     femoral neck chondrosarcoma, 184  
     transdermal fentanyl, 184  
     medical attention, 185  
     patient's life, 186  
     psychiatric issues, 185  
     suicidal ideation, 186  
*Candida albicans*, 123  
 Candidiasis, 339, 340  
 Carcinoid crisis  
   catecholamines, 51  
   chemoembolization of liver, 51  
   symptoms, 51  
 Carcinoid tumors, 50  
 Cardiac arrhythmias  
   bradycardia  
     definition, 60  
     etiologies and mechanisms, 60  
     treatment, 60  
   diagnosis and management, 57, 58  
   etiology, 57  
   tachycardia  
     irregular narrow QRS complex treatment, 62–63  
     regular narrow QRS complex treatment, 61, 62  
     wide QRS complex, 63–64  
 Cardiomyopathy, 266  
 Cardiopulmonary resuscitation (CPR), 190  
 Carreras, M.T.C., 143, 144, 146–159  
 Catecholamine-resistant shock, 321  
 Cefepime, 322  
 Central venous catheter (CVC)  
   and arterial catheters, 214  
   categories, 215  
   catheter-related infection, 216–218  
   diagnosis, 216  
   *Enterococcus*, 218  
   outpatient management, 215  
   pathophysiology and etiology, 216  
 Cerebral edema  
   acute hyperventilation, 15  
   chemotherapeutic agents, 15  
   corticosteroid, 15  
   craniotomy, 16  
   CSF diversion, 15  
   herniation attempts, 16  
   hypertonic saline, 15  
   lumbar puncture, 16  
   mannitol, 15  
   osmotic diuretics, 15  
   tumor debulking, 16  
   types, 15  
 Chaftari, P., 55–5860, 62–79, 82–84, 86–90  
 Chemotherapeutic agents, 30  
   antibiotics, 331, 332  
   antimetabolites, 331

- Chemotherapeutic agents (*cont.*)  
 etoposide, 332  
 platinum agents, 331  
 targeted agents, 332  
 taxanes, 330  
 vinca alkaloids, 332
- Chemotherapy  
 algorithm  
   diphenhydramine, 260  
   hypersensitivity reactions, 259  
   monoclonal antibodies, 260  
   symptoms, 259, 260  
 cytotoxic therapies, 254  
 embryos and fetuses, 329  
 fetal metabolism, 330  
 gastrointestinal motility, 329  
 management strategies, 254  
 monoclonal antibodies, 254  
 organogenesis, 330  
 pregnant woman, 329  
 protocols and education, 254  
 and radiation-related diarrhea  
   antidiarrheal medications, 120  
   capecitabine, 119  
   cytotoxicity, 119  
   5-FU bolus, 120  
   irinotecan, 120  
   loperamide, 120  
   malabsorption/loss, 120  
   mucosal atrophy and fibrosis, 120  
   octreotide, 120  
   weight loss, 120  
 teratogens, 330
- CHF. *See* Congestive heart failure (CHF)
- Chlamydial infection, 342, 343
- Chlorpromazine, 299
- Chronic CRF, 280
- Chronic pain, 276–277
- Claustrophobia, 304
- Clostridium difficile* infection  
 cephalosporins, 118  
 clindamycin, 118  
 clinical manifestations, 118  
 complications, 118  
 diarrhea, 118  
 fecal transplantation, 119  
 fidaxomicin, 119  
 fluoroquinolones, 118  
 leukocytosis, 118  
 metronidazole, 119  
 polymerase chain reaction analysis, 118  
 probiotics, 119  
 treatment, 119  
 vancomycin, 119
- Cole, K.C., 349, 350, 352–357, 359–362,  
 364–366, 368–370
- Communication, 85, 191, 281, 283, 284
- Community-acquired pneumonia (CAP), 199
- Computed tomography (CT) myelography, 5
- Computed tomography pulmonary  
 angiography (CTPA), 225
- Computed tomography venography (CTV), 224
- Congestive heart failure (CHF), 66
- Connective tissue diseases, emergency  
 conditions, 177
- Constipation  
 digital disimpaction, 117  
 fiber supplements, 117  
 ideal prophylactic measures, 117  
 IV replacement, 117  
 laboratory evaluation, 117  
 local impairments, 117  
 opioid agonists, 117  
 radiologic evaluation, 117  
 stimulant laxatives, 117  
 symptoms, 116  
 $\mu$ -opioid GI receptor antagonists, 117
- Corneal ulcers, 374–376
- Coronary artery bypass grafting (CABG), 69
- Corticosteroids, 4, 50, 301
- Cranial nerve dysfunction, 315
- Cranial palsies, 384
- CT myelography. *See* Computed tomography  
 (CT) myelography
- Cuffed endotracheal tubes, 319
- Cyclobenzaprine, 301
- Cytokines  
 interferons, 263  
 interleukin-2, 264
- Cytomegalovirus (CMV) retinitis  
 immunocompromised cancer  
   patients, 381  
 intravitreal injection, 382  
 symptoms, 382  
 visual function, 382
- Cytotoxic agents  
 blood pressure, 265  
 management, 266  
 management strategies, 265  
 TK inhibitor, 264  
 VEGF, 264
- D**
- Dalteparin, 227
- Decision-making, 182  
 EC (*see* Emergency center (EC))  
 ethical values, 182

- informed consent, 190
  - medical treatment, 182
  - physicians, 188
  - Delirium
    - advanced cancer, 290
    - cause of, 290
    - clinical features, 291
    - complication, 290
    - drug-seeking behaviors, 182
    - emotionally traumatic, 290
    - etiology, 293–295
    - mental status/encephalopathy, 290
    - morbidity and mortality, 290
    - neuropsychiatric syndrome, 188
    - nonpharmacologic management, 297, (see also Pain)
    - pathophysiologic mechanism, 292–293
    - pharmacologic management, 298–300
    - prevalence, 290
    - risk factors, 295
    - subtypes, 291–292
    - treatment, 296–297
    - workup, 296
  - Delusions, 306
  - Denileukin diftitox, 260
  - Depression, 307
    - cancer patients, 303
    - Diagnostic and Statistical Manual of Mental Disorders*, 303
    - emotional support and empathic, 304
    - psychostimulants, 304
  - Dermatologic emergencies
    - cancer centers, 350
    - skin disorders, 350
  - Dexamethasone, 317
  - Dexmedetomidine, 300
  - Diabetes insipidus (DI), 24
  - Diabetic ketoacidosis, 39, 40
  - Diaphragmatic dysfunction
    - co-existing conditions, 109
    - diagnostic testing, 109
    - dyspnea, 108
    - etiology, 109
    - parenchymal infiltrates, 109
  - Diarrhea
    - bacterial infections, 118
    - C. difficile*, 118, 119
    - chemotherapy, 119, 120
    - definition, 117
    - GVHD, 120, 121
    - neuroendocrine tumors, 121–122
    - neutropenia, 118
    - neutropenic enterocolitis (typhlitis), 122
    - parasites, 118
    - radiation therapy, 119, 120
    - viral infections, 118
  - Digital ischemia, 176
  - Diphenhydramine, 298
  - Drug extravasation
    - antidotes, 270
    - clinical manifestations, 267
    - factors, 267
    - management strategies, 267–270
    - MD Anderson, 259
  - Drug reaction with eosinophilia and systemic symptoms (DRESS)
    - clinical features, 357–359
    - diagnosis, 359, 360
    - differential diagnosis, 360
    - hypersensitivity syndrome, 357
    - nonblistering drug reaction, 356
    - prognosis, 359
    - therapy, 360, 361
  - Drug-seeking behavior, 186, 187
  - Dyspnea, 94
- E**
- Ectopic pregnancy
    - diagnostic tests, 336
    - medical management, 337
    - methotrexate, 337
    - pelvic examination, 337
    - pregnancy-related deaths, 336
    - risk factors, 336
    - symptoms, 336
    - ultrasonographic detection, 336
    - vaginal bleeding, 337
  - Elsayem, A., 273–284
  - Embolectomy, 229
  - Emergency center (EC)
    - decision-making capacity, 182
    - drug-seeking behaviors, 182
    - patient care, 182
    - political and legal right, 182
    - treatment and disposition, 182
  - Endophthalmitis
    - fungal infiltration, 383
    - ocular surgery, 384
    - postintraocular surgery, 383
    - symptoms, 383
    - treatment, 384
  - Enoxaparin, 227
  - Enterochromaffin cells, 121
  - Erythroderma, 363

**E**

- Candida albicans*, 123
- chemotherapeutic agents, 123
- cytomegalovirus, 123
- dietary modifications, 124
- dysphagia, 123
- endothelial cells, 123
- fibroblasts, 123
- gancyclovir, 123
- odynophagia, 123
- varicella zoster virus, 123

Ewing sarcoma, 317

**F**

Fadul, N., 273–284

Faiz, S., 93–9698–103, 105–110

Farroni, J.S., 181–186, 188–192

**Fatigue**

- assessment, 279–280
- etiology, 279
- life and interfere with patient's ability, 279
- management, 280
- MD Anderson Emergency Center, 279

Febrile neutropenia, 319

Fentanyl, 324

**Fistula**

- pelvic examination, 345
- rectovaginal, 346
- symptoms, 345
- vesicovaginal, 345

4-factor prothrombin complex concentrate (4F-PCC), 243

Fresh frozen plasma (FFP), 243

**G**

Gallagher, C.M., 181–193

Gao, S., 221–249

Gastroparesis, 124

Gemtuzumab ozogamicin, 261

Gonzalez, C.E., 195–218

George, M., 93–9698–103, 105–110, 113–139

**GI bleeding**

- bevacizumab, 129
- capsule endoscopy, 130
- cardiovascular system, 130
- clinical manifestations, 127
- colonoscopy, 128, 130
- community-acquired pathogens, 129
- CT angiography, 130
- esophagogastroduodenoscopy, 130
- etiology, 127
- factors, 127

fresh frozen plasma and platelets, 130

GVHD, 129

injection sclerotherapy and ligation, 130

mucositis, 129

multidisciplinary approach, 127

neutropenic enterocolitis, 129

portal hypertension, 129

proctitis, 129

proton pump inhibitor, 130

proximal causes and contributing factors, 129

radionuclide imaging, 130

small bowel, 128

thoracic neoplasms, 129

timing, 129

upper endoscopy, 127, 128

Glucagon and epinephrine, 41

Glucocorticoids, 38, 39

Gonorrhea, 343

**Graft-versus-host disease (GVHD)**

anesthetic drops, 377

differential diagnosis, 364, 365

electrolyte balance, 362

epidermal necrosis, 362

erythematous maculopapular eruption, 362

morbidity and mortality, 361

necrotic ocular tissue, 378

nonirradiated transfusion, 364

SCT, 376

skin involvement, 362

stage IV, 377

T cell, 361

Gushiken, F., 221–249

**Gynecologic emergencies**

hemodynamic instability, 328

medical history, 328

**H**

Halm, J., 113–139

Hassan, S.A., 55–5860, 62–79, 82–84, 86–90

Healthcare-associated pneumonia (HCAP), 199

**Heart failure emergencies**

chemotherapeutic agents, 74

CHF treatment, 76, 77

classification, 75

definition, 74

diagnosis

ACC/AHA, 76

BNP test, 76

dyspnea, 75

etiology of CHF, 75

framingham criteria, CHF, 75

special considerations, 77, 78

- Hematologic emergencies
  - acute deep VTE and PE (*see* Acute deep VTE)
  - acute hemorrhage (*see* Acute hemorrhage)
  - anemia (*see* Anemia)
  - anemia and thrombocytopenia, 222
  - blood transfusion reactions (*see* Blood transfusion reactions)
  - diagnosis and management, 222
  - HVS (*see* Hyperviscosity syndrome (HVS))
  - hyperleukocytosis (*see* Hyperleukocytosis)
  - immunologic and nonimmunologic phenomena, 222
  - pathologic manifestations, 222
  - thrombocytopenia (*see* Thrombocytopenia)
  - thrombocytosis (*see* Thrombocytosis)
- Hematopoietic stem cell transplantation (HSCT), 361
  - indications, 107
  - pneumonia, 107
  - posttransplantation constrictive bronchiolitis, 108
  - pulmonary complications, 107
  - stem cells, 107
  - timing, 107
- Hematuria, 152–154
- Hemodynamic dysfunction, 316
- Hemoptysis
  - bleeding, 101
  - bronchoscopy and interventional techniques, 101
  - chemotherapy, 101
  - cold saline and local epinephrine, 101
  - CT scan, 101
  - diffuse alveolar hemorrhage, 101
  - Fogarty balloon catheter, 102
  - malignancy/metastatic disease, 101
  - treatment, 101
- Hemorrhage, 334
  - hemodynamic instability, 328
  - sepsis, 330
  - vaginal bleeding (*see* Vaginal hemorrhage)
- Hemorrhagic cystitis
  - acute radiation cystitis, 154
  - BK virus, 154
  - bladder inflammation, 154
  - chemotherapeutic agents, 154
  - cytomegalovirus, 155
  - management, 155
  - symptoms, 154
  - ulcer and fistula formation, 154
  - UTIs, 154
- Heparin-induced thrombocytopenia (HIT), 237, 240
- Hepatic cytochrome P450 system, 301
- Hepatic encephalopathy
  - clinical manifestations, 134
  - liver cirrhosis, 133
  - pathophysiology, 133, 134
  - treatment, 134
- Herpes reactivation, 379, 381
- Herpes simplex virus (HSV) infection, 340, 341
- Herpes zoster ophthalmicus, 379
- Hospital-acquired pneumonia (HAP), 199
- HSCT. *See* Hematopoietic stem cell transplantation (HSCT)
- $\beta$ -human chorionic gonadotropin ( $\beta$ -hCG), 335
- Hymes, S.R., 349, 350, 352–357, 359–362, 364–366, 368–370
- Hyperadrenergic symptoms, 50
- Hypercalcemia
  - central nervous system, 30
  - common humoral factor, 31
  - lowering serum calcium levels, 31
- Hyperglobulinemia, 37
- Hyperglycemia, 321
  - acidosis, 39
  - blood glucose level, 39
  - blurry vision, 38
  - diabetes mellitus, 38
  - serum glucose level, 38
- Hyperkalemia, 151
  - common iatrogenic, 28
  - EKG pattern, 28
  - electrolyte disorder in cancer, 28
  - nonspecific symptoms, 28
  - tumor lysis syndrome, 28
- Hyperleukocytosis, 321, 322
  - acute myeloid leukemia, 230
  - alkalization, 230
  - intracranial hemorrhage, 230
  - leukapheresis, 230
  - primary clinical symptoms, 230
  - pulse oximetry, 230
  - systemic antileukemic therapy, 230
  - treatment, 230
- Hypermagnesemia, 33, 34
- Hypernatremia, 323
  - antidiuretic hormone, 25
  - cellular dehydration, 25
  - excess sodium, 24
  - nephrotoxicity of drugs, 25
  - V2 receptor, 25
- Hyperpigmentation, 43
- Hyperphosphatemia, 37

- Hypersensitivity
- alkylating agents, 257
  - anthracyclines, 257
  - antimetabolites, 257–258
  - asparaginase, 256–257
  - chemotherapy, 255, 258
  - platinum-based agents, 256
  - risk factors, 255
  - symptoms and signs, 255
  - topoisomerase inhibitors, 258
- Hypertension, 78, 79
- Hypertensive emergencies
- ACE inhibitor, 84
  - angiotensin II, 83
  - anticancer agents, 83
  - antihypertension, factors, 82
  - blood pressure, 82
  - CHF, 84
  - definition, 78
  - end-organ damage, 82, 83
  - hypertension mechanism, 79, 80
  - IV drugs, hypertensive crisis, 84, 85
  - mechanism, chemotherapeutic agents, 81
  - medications, 83
  - pulmonary edema, 84
  - renal artery stenosis, 82
  - syndromes, 79
  - therapeutic agents, 84
  - vascular endothelial growth factor, 79
  - $\beta$ -blockers, 84
- Hyperviscosity, 250
- Hyperviscosity syndrome (HVS)
- acute, 229
  - blood viscosity, 229
  - cellular blood components, 229
  - serum viscosity, 229
  - treatment, 229
- Hypocalcemia, 29, 323
- Hypodipsia, 25, 26
- Hypoglycemia, 42
- blood glucose level, 41
  - counterregulatory hormone responses, 41
  - fat and muscle wasting, 41
  - non-islet cell tumor-induced, 42
- Hypokalemia, 26, 27
- Hypomagnesemia, 27, 29, 30, 32, 59, 64
- Hyponatremia
- hypovolemic, 24
  - hypovolemia, 149
  - neurologic symptoms, 23
  - osmolality, 23
  - osmotic demyelination syndrome, 150
  - physical examination, 150
  - plasma electrolytes, 23
  - SIADH, 149
  - symptoms, 150
  - tea and toast syndrome, 149
  - treatment, 150
  - urinary sodium, 24
- Hypoparathyroidism, 29, 30, 37
- Hypophosphatemia
- bone pain, 35
  - neurologic findings, 34
  - oral phosphate, 36
  - osteoblastic, 35
  - renal reabsorption, 35
- Hypopituitarism, 14, 41, 44, 237
- Hypothyroidism, 45–47
- Hypovolemia, 317, 318
- I**
- Iliescu, C., 55–5860, 62–79, 82–84, 86–90
- Imatinib mesylate, 263
- Immunocompromise
- acute infections, 196
  - focal chest signs, 199
- Indwelling tunneled pleural catheters, 98, 99
- Infections
- allogeneic hematopoietic stem cell, 198
  - bimanual examination, 338
  - C. trachomatis*, 338
  - CVC, 215
  - hematopoietic stem cell transplantation, 197
  - immunocompromised cancer, 196
  - N. gonorrhoeae*, 338
  - patient's specific defect, 196
  - pelvic/vulvovaginal, 338
  - treatment approach, 197
- Informed consent, 183, 184
- breast cancer, 183
  - culture, 183
  - decision-making capacity, 183
  - hemoglobin level, 183
  - medical power, 183
  - symptoms, 184
  - treatments and interventions, 184
- Inotropic infusions, 320
- Insulinoma, 42
- Intravenous crystalloid fluid, 40
- Intubation, respiratory failure, 319
- IVC filters, 228
- K**
- Jacobson, K., 195–197199–202, 204–218
- Kayexalate, 29
- Kim, P., 55–5860, 62–79, 82–84, 86–90



- Kim, S.K., 371–373, 375, 377, 378, 380–388  
 Kuerer, H.M., 349, 350, 352–357, 359–362, 364–366, 368–370
- L**
- Lahoti, A., 143, 144, 146–159  
 Leptomenigeal disease, 296, 384, 385  
 Leukapheresis, 230, 321  
 Liu, W., 21–32, 34–36, 38, 39, 41–43, 45–51  
 Lorazepam, 9, 11, 298–300, 302, 305, 306  
 Lowenstein, D.H., 8  
 Low-molecular-weight heparins (LMWHs), 227  
 Lu, H., 161–178
- M**
- Magnetic resonance imaging (MRI), 5, 123, 126, 165, 170, 171, 173, 296, 304, 318, 368, 384  
 Magnetic resonance venography (MRV), 224  
 Malignant airway obstruction  
   bleeding, 104  
   bronchogenic carcinoma, 102  
   bronchoscopy, 103  
   carcinoid tumor, 102  
   chest radiograph, 102  
   comorbid conditions, 102  
   mucus production, 102  
   procedures, 103  
   pulmonary function tests, 102  
   pulmonologists and thoracic surgeons, 104  
   stent placement, 104  
   stridor, 102  
 Malignant bowel obstruction (MBO)  
   anticholinergic agents, 126  
   cancer patients, 125  
   diagnosis, 125  
   endoscopic interventions, 126–127  
   evaluation, 126  
   nasogastric tube decompression, 126  
   ovarian carcinoma, 125  
   surgical management, 126  
 Malignant pleural effusion  
   chest radiographs, 95, 96  
   clinical manifestations, 95  
   etiology, 95  
   flow cytometry data, 96  
   indwelling tunneled pleural catheters, 98, 99  
   talc pleurodesis and medical thoracoscopy, 96  
   thoracentesis, 96, 98
- Malignant spinal cord compression  
 Babinski sign, 5  
 back pain, 4  
 Beevor sign, 5  
 corticospinal tract signs, 4  
 diagnosis  
   back pain/neurologic symptoms, 5  
   bone scanning and positron emission tomography, 6  
   CT myelography, 5  
   MRI, 5  
   X-rays, 6  
 etiology and pathophysiologic mechanisms  
   band-like paresthesia, 3  
   cortical bone destruction, 4  
   corticosteroids, 4  
   thoracic metastases, 3  
   vertebral bodies, 3  
 gnawing/aching pain, 4  
 incontinence/inability, 4  
 leg ataxia, 4  
 lung cancer, 2  
 metastatic spinal lesions, 2  
 oncologic and medical therapies, 2  
 palpation and percussion, 4  
 paraplegia, 2  
 radicular symptoms, 4  
 rectal sphincter tone, 4  
 treatment  
   analgesics, 6  
   complications, 6  
   corticosteroid-based therapy, 6  
   radiation, 7  
   radiosensitive tumors, 7  
   steroids, 6  
   weakness, 4
- Malik, A., 113–139  
 Malnourished patients, 35  
 Markovich, M., 195–197, 199–201, 204–218  
 Matthew, P., 328–347  
 Mays, S.R., 349–369  
 MDR pathogen infection, 202  
 Meropenem, 322, 369  
 Metabolic and endocrine oncologic emergencies  
   adrenal crisis, 43–45  
   carcinoid crisis, 51  
   dysfunction, 23  
   hypercalcemia, 30, 31  
   hyperglycemia, 38, 39  
   hyperkalemia, 28  
   hypermagnesemia, 33, 34  
   hypernatremia, 24, 25  
   hyperphosphatemia, 37

- Metabolic and endocrine oncologic emergencies (*cont.*)
- hypocalcemia, 29
  - hypoglycemia, 41, 42
  - hypokalemia, 26
  - hypomagnesemia, 32
  - hyponatremia, 23, 24
  - hypophosphatemia, 34–36
  - hypothyroidism, 45–47
  - thyrotoxicosis, 47, 48, 50
- 3,4-methylenedioxy-*N*-methylamphetamine, 303
- Meticulous attention, 321
- Microscopic hematuria, 152, 153
- Midgut carcinoid tumors, 51
- Monoclonal antibodies, 74, 129, 166, 254, 260–262
- Moore, J.A., 181–193
- Morbilliform eruption, 358
- Mouhayar, E., 55–5860, 62–79, 82–84, 86–90
- MRI. *See* Magnetic resonance imaging (MRI)
- Multiple myeloma
- acute/chronic kidney disease, 147
  - aggressive treatment, 148
  - and AKI, 147, 148
  - concomitant nephrotoxic medications, 148
  - hypercalcemia, 148
  - neoplastic disorder, plasma cells, 147
  - serum-free light chain, 147
  - Tamm-Horsfall mucoprotein, 147
- Myelofibrosis, 231, 236, 237
- Myelophthitic anemia, 237
- Myositis
- definition, 168
  - emergency conditions, inflammatory, 171
  - paraneoplastic myopathies
    - malignancy, 170
    - pathogenesis of inflammatory, 171
    - Raynaud phenomenon, 170
  - pyomyositis
    - diagnosis, treatment and prognosis, 169–170
    - pathogenesis, 169
    - treatment and prognosis, 171, 172
- Myxedema coma, 46, 47
- N**
- Narcotic analgesic withdrawal, 302
- Narrow QRS complex tachycardia treatment
- irregular
    - AV-blocking agents, 62
    - multifocal atrial, 62
    - TEE, 62
    - ventricular rate control, 62
  - regular
    - sinus and atria, 61
    - SVT, 62
    - $\beta$ -blockers, 61
- National Comprehensive Cancer Network, 115
- Nausea and vomiting
- acupuncture and behavioral therapy, 116
  - agents, 115
  - chemotherapy, 115
  - complications, 115
  - emetic reflex, 115
  - gastroenteritis, 115
  - genesis, 115
  - 5-HT<sub>3</sub> antagonists, 116
  - misconception, 115
  - neurokinin-1 receptor inhibitor, 116
  - pavlovian conditioning, 115
  - prevention, 116
  - prophylaxis, 115
  - radiation therapy, 115
  - serotonin antagonists and steroids, 116
- NCSE. *See* Nonconvulsive SE (NCSE)
- Necrotizing fasciitis
- epidemiology, 365, 366
  - host factors, 365
  - presentation and diagnosis, 367, 368
  - soft tissue infections, 365
  - treatment, 368, 369
- Neuroendocrine tumors
- carcinoids, 121
  - enterochromaffin cells, 121
  - GI hormones, 122
  - lantreotide, 122
  - octreotide, 122
  - pasireotide, 122
  - serotonin levels, 121
  - SST analogs, 122
  - VIPoma syndrome, 122
- Neuroglycopenic symptoms, 41
- Neurotrophic cornea, 376
- Neutropenia
- definitions, 204
  - evaluation and administration, 204
  - lactic acid level measurement, 206
  - microbiology, 204, –205
  - outpatient treatment
    - candidates, 206
    - combination therapy, 207
    - low-risk neutropenic febrile patients, 207
    - monotherapy, 207

- physical examination, 206
  - risk of complications, 205
  - serum galactomannan, 206
  - treatment, 208–210
  - Neutropenic enterocolitis (typhlitis)
    - cecum, 122
    - clinical manifestations, 123
    - hematologic malignancies, 122
    - immunodeficiency, 122
    - mucosal injury, 122
    - treatment, 123
  - Nguyen, K.T.T., 221–249
  - Nonconvulsive SE (NCSE), 8, 11
  - Non-ST-elevation myocardial infarction (NSTEMI), 65, 66
  - Nonsteroidal anti-inflammatory drugs (NSAIDs), 148
  - NSAIDs. *See* Nonsteroidal anti-inflammatory drugs (NSAIDs)
  - NSTEMI. *See* Non-ST-elevation myocardial infarction (NSTEMI)
- O**
- Obstructive uropathy
    - abdominal ultrasonography, 158
    - causes, 157
    - clinical presentation, 158
    - foley catheter, 158
    - intraluminal pressure, 157
    - isotope renography, 158
    - PCN placement, 158
    - radiation-induced fibrosis, 157
    - ureteral stent, 158
  - Ocular toxicity
    - in cancer patients, 372
    - hematologic status, 372
  - Oh, J.H., 253–267/269, 270
  - Okhuysen-Cawley, R., 313–325
  - Oligoarthritis, 163., 167–168
  - Opioid
    - analgesics, 276, 278
    - medications, 284
    - naïve and tolerant, 276, 277
    - nerve
      - hypercoagulable state, 385
      - radiation toxicity, 385
      - swelling, 384
    - pain management, 277
  - Orbital cellulitis, 372, 373
  - Osteoporosis, 173–175
  - Osteoporotic fractures
    - chemoradiation, 173
    - PV, 173, 174
    - treatments, 173
    - vertebral compression, 173
  - Ovarian torsion, 346
- P**
- Packed RBCs (PRBCs), 229
  - Pain
    - cancer patients, 187
    - ethical concerns, 189
    - medications, 187, 188
    - opioid analgesics, 187
    - pancreatic cancer patient
      - paramedics, 188
      - treatment options, 188
  - Palliative care
    - acute pain, 277–278
    - adjuvant analgesics, 279
    - anorexia and cachexia
      - assessment, 281
      - in cancer patients, 280
      - etiology, 280
      - management, 281
    - assessment of fatigue, 279–280
    - assessment of pain
      - functional evaluation, 275
      - medical history, 275
      - psychosocial issues, 276
    - cancer-related fatigue, 279
    - chronic pain, 276–277
    - communication, 283
    - curative, 274
    - definition, 274
    - emergency medicine physicians, 274
    - ethics
      - advance directives, 282
      - cancer patients, 282
      - emergency medicine clinicians, 281
      - principles, 282
    - interdisciplinary team, 283, 284
    - management of fatigue, 280
    - opioid analgesics, 278
    - pain management, 275–279
    - patients with advanced cancer, 279
    - physical and psychosocial distress, 274
    - problems, 274
  - Papilledema, 13, 83, 384–387
  - Paraneoplastic syndrome, 162
    - arthralgia, 168
    - dramatic systemic symptoms, 168
    - polyarthritic, 167
    - RS3PE, 167
    - vascular endothelial growth factor, 168
  - Parathyroid hormone (PTH), 30

- Parathyroidectomy, 31
- Paroxysmal nocturnal hemoglobinuria (PNH), 235
- Parvovirus B19 infection, 237
- PCI. *See* Percutaneous coronary intervention (PCI)
- Pediatrics
- acutely bleeding child, 322
  - age
    - EC affects, 314
    - neonates and young children, 315
    - older children, 315
  - analgesia and sedation, 323–324
  - cancer in extremis, 314
  - cardiogenic shock, 316
  - consciousness, 317
  - diagnosis, 324–325
  - distributive shock, 316
  - electrolyte issues, 323
  - febrile neutropenia and sepsis, 319–321
  - hypovolemia, 316
  - leukemia, 321–322
  - malignancies, 314
  - respiratory distress, 318–319
  - seizures, 317
  - shock, 316
  - spinal cord compression, 317–318
  - transfusion, 322–323
- Percutaneous coronary intervention (PCI), 68
- Pericardial disease-related emergencies
- acute pericarditis
    - anticoagulation, 87
    - chemotherapeutic drugs, 87
    - chest pain, 85
    - colchicine, 87
    - empiric approach, 87
    - etiologies, 85
    - medical management, 87
    - ST elevation, 86
    - troponin, 87
  - cardiac arrhythmias, malignancy, 59, 84
  - diagnosis and management, 84
  - pericardial effusion and tamponade
    - chemotherapeutic, 88
    - constrictive pericarditis, 89, 90
    - echocardiography, 88
    - IV fluid infusion, 88
    - mechanical ventilation, 89
    - medical management, 88
- Perioperative pulmonary issues
- lung resection, 106
  - obstructive sleep apnea, 106
  - postoperative pulmonary complications, 106
    - preoperative evaluation, 106
- Peterson, J.F., 291
- PH. *See* Pulmonary hypertension (PH)
- PID
- CDC, 344
  - C. trachomatis* infection, 343
  - diagnosis, 344
  - gonorrhea and chlamydial infection, 344
- Plasmapheresis, 250
- Platelets, 243
- Platinum-based agents, 256
- Pneumonia
- assessment
    - antibiotics, 201
    - de-escalation, 201
    - diagnostic testing, 200–201
    - and management, 201–204
    - risk assessment, 201
  - definitions, 199
  - epidemiology, 197–199
  - microbiology, 199–200
  - types, 199
- Pneumothorax
- classification, 95
  - clinical manifestations, 95
  - etiology, 95
  - treatment, 95
- Polyarthritis
- carcinomatous, 167
  - paraneoplastic syndrome, 167–168
  - rheumatologic disease, 167
  - RS3PE, 167
  - symptoms, 168
- Posttraumatic stress disorder, 304
- Pregnancy
- in cancer patient, 328, 329
  - chemotherapy, 329, 330
- Procarbazine, 301
- Pseudohyperphosphatemia, 37
- Pseudomonas aeruginosa*, 204
- Psychiatric emergencies
- adverse effects (*see* Adverse effects)
  - agitation (*see* Agitation)
  - alcohol, benzodiazepines and barbiturates, 301–302
  - anxiety, 304–305
  - depression, 303–304, 307
  - individual patients, 308
  - mania, 305
  - narcotic analgesics, 302–303
  - oncology setting, 288
  - pain, 307–308
  - prevalence of suicide, 306–307
  - primary psychiatric disorders, 303–306

psychiatric disorders, 288  
 psychosis, 306  
 recreational drugs, 303  
 risk factors, 307, 308  
 suicidality, 288  
 suicidal patients, evaluation of, 308–310  
 treatment recommendations, 310  
**Psychosis**  
 agitation, 306  
 delusions, 306  
 depression-related, 303  
 schizophrenia, 306  
**Psychotropics**, 301  
**Pulmonary artery sarcoma**, 105  
**Pulmonary Embolism Severity Index (PESI)**,  
 225–226  
**Pulmonary hypertension (PH)**, 105  
**Pulmonary leukostasis**, 230  
**Pulmonary rehabilitation**, 109  
**Pulmonary vascular disease**  
 chronic myeloproliferative  
 disorders, 105  
 necropsy, 105  
 PH, 105  
 transthoracic Doppler  
 echocardiography, 105  
 tumor obstruction, 105  
 ventilation perfusion scans, 105  
  
**Q**  
**QT interval prolongation**, 57  
  
**R**  
**Radiation**  
 blastocyst stage, 333  
 central nervous system development, 333  
 in pregnant patients, 333  
 utero exposure, 333  
**Radiation-induced lung injury**  
 chemotherapeutic agents, 100  
 corticosteroids, 100  
 medications, 100  
 modalities, 100  
 pneumonitis, 99  
 radiologic findings, 100  
**Radionuclide venography**, 224  
**Raynaud phenomenon**, 176  
**Re-epithelialization**, 356  
**Refusal**  
 emergency physician, 184  
 informed consent, 183  
**Relapsed lymphoma**, 386

**Resuscitation**  
 ethical challenges  
 decision-making capacity, 190  
 EC, 191  
 faith and cultural traditions, 192  
 in life-threatening situations, 191  
 medical decisions, 191  
 medical ethics, 192  
 medical treatment, 191  
 physicians, 192  
 values and principles, 192  
 left knee pain  
 blood pressure, 190  
 EC physician, 190  
 electrical activity, 190  
 ileac vs. aneurysm versus  
 thrombosis, 190  
**Reticulocyte index (RI)**, 232–233  
**Reversible posterior leukoencephalopathy  
 syndrome**, 8  
**RIFLE. See Risk, injury, failure, loss and  
 end-stage renal disease (RIFLE)**  
**Risk, injury, failure, loss and end-stage renal  
 disease (RIFLE)**, 144  
**Rituximab**, 261

## S

*Saccharomyces boulardii*, 119  
 Safe, effective pain management, 186  
 Sahai, S.K., 313–325  
 Salahudeen, A.K., 143, 144, 146–159  
 Schlumbrecht, M.P., 327–347  
**Seizures**  
 abnormalities, 8  
 agents, 9  
 buccal midazolam, 10, 11  
 definition, 8  
 diagnostic testing, 9  
 diazepam, 10  
 etiologies, 8  
 intubation, 9  
 lacosamide, 10  
 LEV, 10  
 lorazepam, 9  
 midazolam and midazolam, 10  
 NCSE, 8  
 reversible posterior leukoencephalopathy  
 syndrome, 8  
**Sepsis**, 213, 214  
 assessment and management, 211–212  
 diagnosis  
 cultures, 213  
 empiric combination therapy, 214

- Sepsis (*cont.*)
- hypotension, 214
  - interventions/early goal-directed therapy/bundles, 213–214
  - laboratory tests, 213
  - supportive therapy, 214
  - definition, 210–211
  - epidemiology, 211
  - evaluation and management, 210
  - infection and definitions, 211
  - urine formation, 211
  - white blood cell, 211
- Septic arthritis
- acute leukemia, 163
  - clostridium septicum*, 163
  - fungal infections, 164
  - glucocorticoids, 163
  - immune function, decrease, 163
  - mycobacterial infection, 164
  - radiation therapy, 163
  - staphylococcus aureus, 163
- Serotonin syndrome, 301
- Serum cortisol measurement, 45
- Serum lactate dehydrogenase (LDH) level, 223
- Severity-of-illness score for TEN (SCORTEN), 354
- Sexually transmitted infection (STI), 339
- SIADH. *See* Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
- Side effects
- hypersensitivity, 254
  - interleukin-2, 264
  - protocols and education, 254
  - VEGF inhibitors, 264
- SJS-TEN. *See* Stevens-Johnson syndrome (SJS)
- Sodium chloride tablets, 24
- Space-occupying lesions
- blood pressure management, 17
  - brain metastasis, 13
  - central nervous system infections, 2
  - clinical presentation, 14
  - coagulopathy, 17
  - diagnosis, 13
  - location-related symptoms, 14
- Spontaneous bacterial peritonitis
- ascitic fluid, 133
  - diagnosis, 133
  - hepatorenal syndrome, 133
  - high-dose fluoroquinolones, 133
  - metastatic disease, 132
  - third-generation cephalosporin, 133
- Spurious hypokalemia, 321
- Staphylococcal scalded skin syndrome (SSSS), 355
- ST-elevation myocardial infarction (STEMI), 65
- STEMI. *See* ST-elevation myocardial infarction (STEMI)
- Stevens–Johnson syndrome (SJS)
- causative medication, 352
  - chemotherapeutic agents, 351
  - classification, 352
  - complications, 353–, 354
  - diagnosis, 354–, 355
  - epidermal detachment, 354
  - GVHD, 355
  - medications, 350
  - mucocutaneous drug reaction, 350
  - mucosal disease, 352
  - painful red patches, 352
  - pathology, 355
  - prognosis, 354
  - therapy, 355–, 356
- Suarez-Almazor, M.E., 161–178
- Substance intoxication and withdrawal syndromes
- alcohol, 301–302
  - barbiturates, 301–302
  - benzodiazepines, 301–302
  - narcotic analgesics, 302–303
  - recreational drugs, 303
- Suicidal ideation, 309
- Suicide risk assessment, 288
- Supraventricular tachycardia (SVT), 61, 62
- Surgical wound infections
- abscess formation, 215
  - anesthesia, 215
  - bacterial/fungal contamination, 214
  - signs and symptoms, 215
- Suspicion, 325
- Symptoms
- advanced cancer, 279
  - palliative care, 280
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 149
- Syphilis
- benzathine, 342
  - maculopapular rash, 342
  - multiorgan dysfunction, 342
  - nontender ulcer, 341
  - Treponema pallidum*, 341
- Systemic steroids, 356
- T**
- Tamponade, 88, 89
- Targeted therapy
- bortezomib, 262
  - erlotinib, 262

- management strategies, 263
  - Sorafenib, 262
  - Taxanes
    - paclitaxel, 256
    - polyethoxylated castor oil, 256
    - symptoms, 256
  - Temsirolimus, 263
  - Thekdi, S.M., 287–291, 293, 295–311
  - Thionamide drugs, 49
  - Thoracentesis, 98
  - Thrombocytopenia, 250, 322
    - agents with thrombopoietic activity, 239
    - bleeding, 237
    - bortezomib, 239
    - chemotherapy, 239
    - definition, 237
    - etiologies, 238
    - heparin-based therapy, 240
    - HIT, patients with, 237
    - immune-mediated thrombocytopenia, 239
    - lenalidomide, 239
    - management, 239
    - myelodysplastic syndrome, patients with, 239
    - PF4-heparin complex, 240
    - platelet transfusion, 239
    - primary idiopathic immune thrombocytopenia, 239
    - radiation therapy, 239
    - risk of, 240
    - severity of, 239
    - TMA, 239
  - Thrombocytosis
    - cytoreductive therapy, 231
    - definition, 231
    - patients, 231
    - reactive thrombosis, 231
    - symptomatic primary thrombocytosis, 231
    - symptoms and complications, 231
  - Thrombolytic therapy, 228
  - Thrombotic microangiopathy (TMA), 239
  - Thyroid hormone replacement therapy, 47
  - Thyroid storm, 48, 49
  - Thyroid-stimulating hormone (TSH), 46
  - Thyrotoxicosis
    - contrast agents, 50
    - hyperadrenergic state, 47
    - hyperthyroidism, 47
    - neuropsychiatric symptoms, 47
    - propranolol, doses of, 50
    - thyroid diseases, 48
  - Toale, K.M., 1–18
  - Toxic epidermal necrolysis (TEN). *See* Stevens–Johnson syndrome (SJS)
  - Trastuzumab, 261
  - Trichomoniasis, 339
  - Tummala, S., 1–18
  - Tumor lysis syndrome (TLS)
    - AKI, 148
    - alkalinization, 149
    - chemotherapy, 148
    - electrocardiogram abnormalities, 149
    - glomerular filtration, 149
    - hyperkalemia, 148
    - hyperphosphatemia and secondary hypocalcemia, 148
    - risk factors, 148
    - serum uric acid levels, 149
    - uric acid, 148
  - Tumor-induced (oncogenic), 35
- U**
- UA. *See* Unstable angina (UA)
  - Ulceration and ecchymoses, 367
  - Ultrasonography (US), 224
  - Unstable angina (UA), 65, 66
  - Urinary diversions
    - acidosis and volume depletion, 152
    - chronic metabolic acidosis, 152
    - intestinal epithelium, 152
    - metabolic abnormalities, 152
    - ureterorectal anastomosis, 151
  - Urinary tract infection (UTI)
    - acute cystitis, 156
    - empiric antibiotic therapy, 156
    - neutropenia and chronic immunosuppression, 155
    - pathogens, 155
    - pseudomonas infection*, 156
    - pyelonephritis, 156
    - risk factors, 155
    - symptoms, 156
    - urinary diversions, 156
    - vancomycin, 156
  - UTIs. *See* Urinary tract infections (UTIs)
- V**
- V/Q scintigraphy (V/Q scan), 225
  - Vaginal hemorrhage
    - cervix and vagina, 335
    - diagnosis, 335
    - pregnancy test, 334
    - prothrombotic activity, 335
    - trophoblastic disease, 335
    - ultrasonographic confirmation, 335
    - urine pregnancy test, 334
  - Vancomycin, 17, 119, 134, 156, 208, 209, 217, 320, 322, 324, 369, 384

- Vascular endothelial growth factor (VEGF),  
264, 265
- Vasculitis and vasculopathies  
  hematologic malignancy, 175  
  immunocomplexes, tumoral antigens, 175  
  paraneoplastic, 176  
  Raynaud phenomenon and digital  
  ischemia, 176
- Ventilator-associated pneumonia (VAP), 199
- Ventricular tachycardia, 63
- Vesicants, 268
- VIPoma syndrome, 122
- Viral urinary tract infections (UTIs), 154
- Vitamin K deficiency, 243
- Vu, K., 221–249
- W**
- Warfarin, 62, 228, 242–244
- Wide QRS complex tachycardia  
  fibrillation treatment, 63–64  
  SVT treatment, aberrancy, 64  
  ventricular, 63
- Wood, S., 287–310
- Y**
- Yeung, S.-C.J., 21–51
- Z**
- Ziprasidone, 300